Bruker Co. (NASDAQ:BRKR) had its target price hoisted by Cowen and Company from $25.00 to $27.00 in a note issued to investors on Thursday, May 4th. The brokerage presently has a “market perform” rating on the medical research company’s stock. Cowen and Company’s target price would suggest a potential upside of 2.94% from the stock’s current price.
BRKR has been the topic of several other reports. Jefferies Group LLC lifted their price target on shares of Bruker from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday, February 14th. Cleveland Research raised shares of Bruker from a “neutral” rating to a “buy” rating in a report on Thursday, April 27th. Evercore ISI lifted their price target on shares of Bruker from $23.50 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, February 14th. Barclays PLC lifted their price objective on shares of Bruker from $22.00 to $24.00 and gave the stock a “hold” rating in a research note on Tuesday, February 14th. Finally, Janney Montgomery Scott downgraded shares of Bruker from a “buy” rating to a “neutral” rating in a research note on Monday, March 27th. Twelve investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $25.00.
Bruker (NASDAQ:BRKR) traded up 0.15% during trading on Thursday, reaching $26.23. The company had a trading volume of 661,725 shares. Bruker has a 12-month low of $19.59 and a 12-month high of $27.05. The stock has a market capitalization of $4.19 billion, a P/E ratio of 27.85 and a beta of 0.98. The stock has a 50 day moving average of $23.95 and a 200-day moving average of $23.19.
Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.19 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.19. Bruker had a net margin of 9.53% and a return on equity of 27.77%. The business had revenue of $384.90 million for the quarter, compared to analyst estimates of $372.59 million. During the same period in the previous year, the company earned $0.21 earnings per share. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts forecast that Bruker will post $1.09 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 23rd. Investors of record on Monday, June 5th will be given a dividend of $0.04 per share. The ex-dividend date is Thursday, June 1st. This represents a $0.16 dividend on an annualized basis and a yield of 0.61%. Bruker’s dividend payout ratio is presently 16.84%.
TRADEMARK VIOLATION NOTICE: “Cowen and Company Boosts Bruker Co. (BRKR) Price Target to $27.00” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/05/20/bruker-co-brkr-price-target-raised-to-27-00-updated.html.
In other news, CEO Frank H. Laukien acquired 73,000 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was acquired at an average price of $26.22 per share, for a total transaction of $1,914,060.00. Following the completion of the transaction, the chief executive officer now owns 37,750,851 shares in the company, valued at approximately $989,827,313.22. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Frank H. Laukien bought 1,920 shares of the business’s stock in a transaction dated Tuesday, May 16th. The shares were bought at an average cost of $25.88 per share, with a total value of $49,689.60. Following the purchase, the chief executive officer now directly owns 37,712,851 shares of the company’s stock, valued at $976,008,583.88. The disclosure for this purchase can be found here. Insiders have purchased 81,520 shares of company stock valued at $2,118,714 over the last 90 days. 35.80% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC bought a new stake in Bruker during the third quarter worth approximately $136,000. Advisory Services Network LLC bought a new stake in Bruker during the first quarter worth approximately $150,000. Acrospire Investment Management LLC boosted its stake in Bruker by 75.8% in the third quarter. Acrospire Investment Management LLC now owns 7,192 shares of the medical research company’s stock worth $163,000 after buying an additional 3,100 shares in the last quarter. Pacad Investment Ltd. boosted its stake in Bruker by 100.0% in the fourth quarter. Pacad Investment Ltd. now owns 7,800 shares of the medical research company’s stock worth $165,000 after buying an additional 3,900 shares in the last quarter. Finally, Capstone Asset Management Co. bought a new stake in Bruker during the first quarter worth approximately $203,000. 69.45% of the stock is owned by institutional investors and hedge funds.
Bruker Company Profile
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Company’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST).
Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.